Catch up on a variety of FDA news in radiology from the past week.
|Articles|November 15, 2000
SmartMeds, Air2Web partner on interactive apps
SmartMeds, Air2Web partner on interactive appsSmartMeds.com, a subsidiary of Infu-Tech, has closed an agreement with Air2Web to develop applications for HMOs, physicians, and patients using Air2Web's wireless Internet platform. The companies
Advertisement
SmartMeds, Air2Web partner on interactive apps
SmartMeds.com, a subsidiary of Infu-Tech, has closed an agreement with Air2Web to develop applications for HMOs, physicians, and patients using Air2Web's wireless Internet platform. The companies are creating software that will enable customers using two-way wireless text messaging or Web-enabled cell phones to get health news, information, and services, including prescription refills. The firms are launching a pilot program with 1500 members of New York City-based HMO Care Plus.
Search Again Return To HNN Homepage
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Radiology Roundup of FDA News: September 13 — September 19
2
Does kV Still Matter in Photon-Counting CT?
3
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
4
Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
5